Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.9450 (-0.67%) ($5.9450 - $5.9450) on Thu. Feb. 25, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.54% (three month average) | RSI | 56 | Latest Price | $5.9450(-0.67%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | ADAP declines -3.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) IFRA(44%) PAVE(39%) IVE(37%) XME(37%) BLOK(35%) | Factors Impacting ADAP price | ADAP will decline at least -2.27% in a week (0% probabilities). TLT(-61%) VCIT(-38%) UUP(-18%) LQD(-18%) TIP(-17%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.27% (StdDev 4.54%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $6.18 | 5 Day Moving Average | $6.04(-1.57%) | 10 Day Moving Average | $6.25(-4.88%) | 20 Day Moving Average | $6.18(-3.8%) | To recent high | -13.1% | To recent low | 14.8% | Market Cap | $919m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |